VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ESH AL 2020 | OPTIC: ponatinib in resistant chronic-phase CML

Jorge Cortes, MD, Georgia Cancer Center, Augusta University, Augusta, GA, outlines the interim analysis of the Phase II OPTIC trial (NCT02467270) of ponatinib in patients with chronic-phase chronic myeloid leukemia (CML) who are resistant or intolerant to prior tyrosine-kinase inhibitor therapy. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter